Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Pain
Interventions: Omnitram, Tramadol, Placebo; Drug
Lead sponsor: Syntrix Biosystems, Inc.; Industry
Eligibility: 21 Years to 55 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Obesity
Interventions: CP-741,952; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 5
States / cities: Ann Arbor, Michigan • Kalamazoo, Michigan • New York, New York + 2 more

Conditions: Respiratory Tract Infections
Interventions: PF-04287881, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hepatic Impairment
Interventions: seladelpar; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions: MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Glendale, California • Long Beach, California • Panorama City, California + 7 more

Conditions: Healthy, Hypoxia
Interventions: Arterial line, Motion; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Boulder, Colorado

Conditions: Hepatitis C
Interventions: GSK2336805; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Pneumococcal Disease
Interventions: 31 valent pneumococcal conjugate vaccine, PCV20, PCV21; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,049 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 30
States / cities: Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more

Conditions: Healthy Volunteer
Interventions: D-2570, Placebo; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Long QT Syndrome
Interventions: LQT-1213, Placebo, Dofetilide 250 μg Cap; Drug
Lead sponsor: Thryv Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Rheumatoid Arthritis
Interventions: CFZ533, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Anniston, Alabama • Miami, Florida • South Miami, Florida + 2 more

Conditions: Gout
Interventions: RDEA3170 and Placebo; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: PF-06823859, Placebo injection SC/IV; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: Placebo, QBW251; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 9
States / cities: Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more

Conditions: Pneumococcal Disease
Interventions: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo; Biological
Lead sponsor: Vaxcyte, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more

Conditions: Healthy
Interventions: single dose NJ-39758979/ matching placebo, multi-dose JNJ-39758979 /matching placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Cypress, California

Conditions: Rheumatoid Arthritis
Interventions: Tirabrutinib, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Orlando, Florida + 6 more

Conditions: Paroxysmal Nocturnal Hemoglobinuria
Interventions: Humanized anti-Factor Bb monoclonal antibody, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Healthy
Interventions: Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: MZE001, Placebo; Drug
Lead sponsor: Maze Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tustin, California

Conditions: Healthy
Interventions: HIP2B, Placebo; Drug
Lead sponsor: CureDM; Industry
Eligibility: 19 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Subjects
Interventions: TAVO103A, Placebo; Drug · Other
Lead sponsor: Tavotek Biotherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Search by objective public record fields.

Omnitram Pharmacokinetic Study In Healthy Volunteers

Safety, Toleration and Efficacy of CP-741,952 for the Treatment of Obesity

Multiple Oral Dose Safety, Tolerability And Pharmacokinetic Study Of PF-04287881 In Healthy Adult Subjects

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion

Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

Healthy Volunteer Study

Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly)

Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

Single and Multiple Dose Study in Japanese Subjects

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

A Study to Test if SAR443809 is Tolerated and Safe When Taken as a Single Dose in Healthy Adults

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

A Randomized Phase 1 of of MZE001 in Healthy Volunteers

A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects

Study of TAVO103A in Healthy Volunteers

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects